Filing Flows › Arbutus Biopharma (ABUS) › Q4 2024
Arbutus Biopharma (ABUS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
Arbutus Biopharma (ABUS) reported revenue of $1.6M for the fourth quarter 2024 (Q4 2024), -27% from a year earlier and +18% from the quarter before. Operating margin was -885.2%, net loss $12.5M (796.2% of revenue).
Arbutus Biopharma, Q4 2024: revenue $1.6M (-27% year over year), operating margin -885.2%, net loss $12.5M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +18% | -27% |
| Operating profit | −$13.9M | — | — |
| Net earnings | −$12.5M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $1.6M in Q4 2024, down 27% year over year and up 18% from the previous quarter. Collaborations and licenses was the largest line at 67% of revenue.
Operating costs exceeded revenue by $13.9M, an operating margin of -885.2%. Total costs fell 32% while revenue fell 27%. The fastest-growing cost line was Other operating costs (+774%). The quarter ended with a net loss of $12.5M, narrower than the previous quarter's $19.7M loss.
Operating cash flow was −$10.3M. Non-cash charges added back $333K of depreciation and amortization and $1.6M of share-based compensation. Capital expenditures of $86K exceeded it, leaving free cash flow of −$10.4M.
Questions
What was Arbutus Biopharma's revenue in the fourth quarter 2024?
Arbutus Biopharma (ABUS) reported revenue of $1.6M for the fourth quarter 2024 (Q4 2024), -27% from a year earlier and +18% from the quarter before.
Was Arbutus Biopharma profitable in the fourth quarter 2024?
Operating loss was $13.9M (-885.2% of revenue) and net loss $12.5M.
Source: Arbutus Biopharma 10-K on SEC EDGAR.